Literature DB >> 15781162

Contrast-induced nephropathy.

Peter A McCullough1, Sandeep S Soman.   

Abstract

Contrast-induced nephropathy (CIN) is a leading cause of in-hospital acute renal failure in critically ill patients who undergo radiographic procedures. Critical care patients are at particular risk, often because of baseline renal dysfunction, older age, and the presence of diabetes. In addition, there are superimposed risks, including volume depletion, sepsis, and use of nephrotoxic drugs. The rates of CIN (defined as an increase in serum creatinine by >25% or 0.5 mg/dL) can be predicted by using multivariate tools. Prevention measures include adequate hydration, use of N-acetylcysteine and iso-osmolar contrast, and for patients who are at the highest risk, prophylactic hemofiltration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781162     DOI: 10.1016/j.ccc.2004.12.003

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  37 in total

1.  Protective effect of beta-glucan on contrast induced-nephropathy and a comparison of beta-glucan with nebivolol and N-acetylcysteine in rats.

Authors:  Eyup Koc; Kadriye Altok Reis; Fatma Ayerden Ebinc; Hatice Pasaoglu; Canan Demirtas; Suna Omeroglu; Ulver Boztepe Derici; Galip Guz; Yasemin Erten; Musa Bali; Turgay Arinsoy; Sukru Sindel
Journal:  Clin Exp Nephrol       Date:  2011-04-26       Impact factor: 2.801

2.  Off-label use of intravascular iodinated organic and MR contrast media.

Authors:  O Tamburrini; I Aprile; C Falcone; D Console; A Rotundo; A Rotondo
Journal:  Radiol Med       Date:  2010-10-27       Impact factor: 3.469

Review 3.  Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma.

Authors:  Matthew K Tollefson; Naoki Takahashi; Bradley C Leibovich
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

4.  Feasibility of 320-row area detector CT coronary angiography using 40 mL of contrast material: assessment of image quality and diagnostic accuracy.

Authors:  Rihyeon Kim; Eun-Ah Park; Whal Lee; Jin Wook Chung
Journal:  Eur Radiol       Date:  2016-02-23       Impact factor: 5.315

5.  Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention.

Authors:  Wenhua Li; Yaren Yu; Haiyan He; Jing Chen; Debin Zhang
Journal:  Biomed Rep       Date:  2015-04-16

6.  Association between Platelet-to-Lymphocyte Ratio and Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.

Authors:  Muhammed Bora Demircelik; Alparslan Kurtul; Hakan Ocek; Muzaffer Cakmak; Cagın Ureyen; Beyhan Eryonucu
Journal:  Cardiorenal Med       Date:  2015-02-07       Impact factor: 2.041

Review 7.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

8.  Metabolic Syndrome and the Iodine-Dose/Creatinine Clearance Ratio as Determinants of Contrast-Induced Acute Kidney Injury.

Authors:  Ali Amiri; Reza Ghanavati; Hassan Riahi Beni; Seyyed Hashem Sezavar; Mehrdad Sheykhvatan; Mahsa Arab
Journal:  Cardiorenal Med       Date:  2018-06-15       Impact factor: 2.041

9.  Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting.

Authors:  Alice M Mitchell; Alan E Jones; James A Tumlin; Jeffrey A Kline
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

10.  Ferrotoxicity and its amelioration by endogenous vitamin D in experimental acute kidney injury.

Authors:  Chandrashekar Annamalai; Rajesh N Ganesh; Pragasam Viswanathan
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.